Vivus has reported the positive results from the Phase III clinical trial of Avanafil, a potential treatment for erectile dysfunction following a radical prostatectomy.

The randomised, double-blind, placebo-controlled, parallel group and multicentre TA-303 study included 298 men and showed that the drug improved the erectile function in difficult-to-treat patients following bilateral, nerve-sparing, radical prostatectomy.

The adverse effects seen with the use of drug included headache, flushing and nasopharyngitis.

Avanafil is a selective phosphodiesterase type 5 inhibitor.